25 results about "OralSuspension" patented technology

An oral suspension pharmaceutical composition is disclosed for water soluble salts of arylalkanoic acid (NSAID) drugs such as ibuprofen and naproxen. When mixed with glyceryl esters such as glyceryl caprate / caprylate and water, the resulting combination forms a “liquid scaffold” structure that reliably enables the suspension of significant quantities of said arylalkanoic acid drugs. For example, suspensions containing 25% w / w arylalkanoic acid may be obtained using the aforementioned combination. Suspensions comprising further pharmaceutically active agents, in addition to said arylalkanoic acids, may also be prepared. Also disclosed is a binary blend of glyceryl caprate / caprylate and the sodium salt of ibuprofen and a ternary blend of glyceryl caprate / caprylate and the potassium salt of ibuprofen.

This invention belongs to the field of pharmaceutical formulation technology and provides a vinpocetine suspension and its preparation method. The vinpocetine suspension of this invention comprises the following raw materials in specific mass parts: vinpocetine, a suspending agent, a solubilizer, a stabilizer, and water. The vinpocetine suspension of this invention is suitable for oral administration. The excipients in the suspension include a suspending agent, a solubilizer, and a stabilizer. The solubilizer inhibits the aggregation of vinpocetine nanoparticles and improves the solubility and dispersion uniformity of vinpocetine nanoparticles in water. The suspending agent and stabilizer together construct a spatially stable structure, ensuring the suspension and dispersion of vinpocetine nanoparticles and resisting sedimentation. The suspending agent, solubilizer, and stabilizer work synergistically to achieve nanoscale distribution and uniform dispersion and suspension of vinpocetine, significantly improving the bioavailability of vinpocetine. High-pressure homogenization achieves nanoscale distribution of vinpocetine, with a particle size of 200-300 nm.

The present invention provides a liquid composition comprising effective amount of Hydroxyurea for oral administration. The invention further discloses liquid formulation in form of ready to use oral suspension which remains stable at room temperature at the time of dispensing, storage and even after reopening of the container comprising the suspension. Also provided is a method of preparing the formulation and treating sickle cell anemia in pediatric patients.

An oral formulation of granules of an active ingredient such as gepotidacin or a pharmaceutically acceptable salt thereof that rapidly disperses in water, or an oral formulation comprising such granules. Such granules provide an oral suspension with good mouthfeel and palatability. This oral suspension is particularly useful for pediatric patient populations or patient populations with difficulty swallowing.

The present invention discloses a sodium zirconium cyclosilicate oral suspension and a preparation method thereof, which comprise the following components in mass percentages: 10-30% of sodium zirconium cyclosilicate, 0.1-2.0% of cellulose, 0.01-0.30% of suspending agent, 0-10% of flavoring agent, 0-1.0% of preservative, and purified water; the suspending agent is a mixture of xanthan gum and locust bean gum. The potassium ion exchange capacity of the sodium zirconium cyclosilicate oral suspension of the present invention is equivalent to that of the commercially available powder and has good dispersion stability.

The invention belongs to the technical field of pharmaceutical preparations, and relates to an anhydroicaritin nanocrystal oral suspension and a preparation method thereof. The oral suspension contains anhydroicaritin nanocrystals, a suspending aid, a surfactant, a buffer salt system and other pharmaceutically acceptable auxiliary materials. By optimizing the surfactant system and the pH range, the stability of the anhydroicaritin is effectively improved. The problem of long-term stability of a nanocrystalline oral suspension preparation prepared from anhydroicaritin is solved. According to the prescription, the dissolution speed of the medicine is increased, the bioavailability is improved, and the preparation method is easy to operate, stable in process and suitable for industrial production.

This invention discloses an oral suspension of an anti-tuberculosis drug and its preparation method. The oral suspension contains an anti-tuberculosis drug, a suspending agent, a surfactant, an antibacterial agent, an antioxidant, a flavoring agent, and a pH adjuster. It has technical advantages such as stable physical and chemical properties, uniform content, and easy long-term storage.

The present invention relates to stable liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable oral suspensions of baclofen at concentrations of equal to or more than 2 mg / mL or more are provided. Preferably, the liquid pharmaceutical compositions of baclofen are suitable for oral administration and are stable at wider pH ranges over a variety of storage conditions, including long-term storage for extended periods of time. Methods of treating various disorders using the inventive pharmaceutical compositions are also provided. The invention further relates to various methods for preparing stable suspension of baclofen.

The invention discloses a stable eplerenone oral suspension and a preparation method thereof. According to the oral suspension, a buffer pair pH regulator is adopted to regulate the pH value of the oral suspension of the system to 3.0-5.0, so that the stability of the product in the storage process is maintained. Meanwhile, compared with eplerenone tablets, the eplerenone oral suspension provided by the invention has the advantages that the absorption is faster, the in-vivo exposure of the medicine is larger, the bioavailability is obviously improved by about 50%, and a reliable high-stability and high-bioavailability eplerenone oral suspension preparation scheme is provided clinically.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to anhydroicaritin nanocrystalline oral suspension and a preparation method thereof. The oral suspension disclosed by the invention contains anhydroicaritin nanocrystals, a space protecting agent, a surfactant, a preservative, a pH regulator and other pharmaceutically acceptable auxiliary materials. Compared with the prior art, the problem that the stability is poor after the anhydroicaritin is prepared into the nanocrystal is solved; particle size distribution is uniform, and aggregation and layering phenomena are avoided; related substances are controllable, the safety is higher, the taste is good, the dosage can be accurately divided according to the body weight, and children, old people and patients with dysphagia can take the medicine conveniently. The oral suspension is simple in preparation method and suitable for industrial production.

This application relates to the field of medicine, and specifically discloses a fexofenadine hydrochloride oral suspension and a preparation method thereof. The oral suspension includes an active ingredient and excipients. The active ingredient is fexofenadine hydrochloride, and the excipients at least include a flavoring agent, a suspending agent, a preservative, and a dispersing aid. The suspending agent includes one or both of sodium carboxymethylcellulose and hydroxypropyl methylcellulose; the dispersing aid is a mixture of polyvinylpyrrolidone and gelatinized modified microcrystalline cellulose; the preparation method includes the following steps: S1. Add water, then add a buffer solution, stir to dissolve, add the dispersing aid, and then add fexofenadine hydrochloride, and stir to obtain raw material A; S2. Mix water and the preservative to obtain raw material B; S3. Add the suspending agent to raw material A, then add raw material B, mix and stir, add the flavoring agent, and add the remaining water to make up the volume to obtain the product. This application has the advantage that the prepared fexofenadine hydrochloride oral suspension has good redispersibility.

The present invention provides a manufacturing method of rilpivirine oral suspension with a specific loading of rilpivirine of 30-35 mg / mL. The oral suspension produced have a controlled pH and thixotropy, which are essential to facilitate the dissolution of rilpivirine hydrochloride into and even distribution and stability maintenance of the rilpivirine in the suspension, optimizing shelf life and efficacy of the suspension while also enabling convenient and palatable administration.

The invention discloses a fumaric acid Vonoprazan suspension and a preparation method thereof, the fumaric acid Vonoprazan suspension is prepared from fumaric acid Vonoprazan, a suspending aid, a wetting agent, an acidifying agent, a flavoring agent and essence, the prepared preparation is easier to swallow compared with tablets, proper auxiliary materials are screened and added through a prescription, the bitter taste of the fumaric acid Vonoprazan during oral administration is obviously reduced, and the oral administration effect of the fumaric acid Vonoprazan is improved. The clinical compliance of a patient is improved; and the defects that the tablet is taken after being broken apart, the dosage is not accurate enough, the coating is damaged and the taste masking effect is influenced are overcome. The oral suspension is packaged in unit dose, and is accurate in dose and convenient to administrate.

Pharmaceutical compositions comprising oil as a vehicle, a suspending agent, and a surfactant are disclosed to be used in conjunction with temozolomide.

The invention discloses a preparation method of an atorvastatin calcium oral suspension, and belongs to the technical field of pharmaceutical preparations. The preparation method provided by the invention comprises the following steps: adding part of water into a liquid preparation container, heating and carrying out nitrogen filling treatment, then adding a preservative and part of a suspending aid, and stirring to obtain first liquid; the suspending aid comprises Arabic gum; adding a part of water into another container, carrying out nitrogen charging treatment, then adding the remaining suspending aid and atorvastatin calcium, carrying out shearing dispersion, then mixing with the second liquid, then adding a flavoring agent and the remaining water, carrying out volume metering and nitrogen charging, and controlling the dissolved oxygen content to be less than 3mg / L; and filling into a bottle purged by nitrogen, carrying out headspace nitrogen charging after the filling is finished, so that the residual oxygen content in the bottle is below 5%, and sealing a cover. According to the invention, the physical stability and chemical stability of the atorvastatin calcium oral suspension are remarkably improved, and meanwhile, compared with the existing dosage form, the dosage form of the obtained oral suspension has better patient compliance and flexibility.

This invention discloses a perampanel oral suspension and its preparation method. The preparation method of this invention includes the following steps: S1, adding microcrystalline cellulose sodium carboxymethyl cellulose co-treatment material to water for homogenization to obtain a first dispersion; S2, adding sorbitol, an antibacterial agent, and a pH adjuster to the first dispersion to obtain a second dispersion; S3, pulverizing perampanel and sieving it to control the particle size D. 90 The sample size is 10–15 μm; S4, the perampanel obtained in step S3 is subjected to antistatic treatment; S5, the perampanel treated in step S4, defoamer, and polyoxyethylene hydrogenated castor oil are added to the second dispersion to obtain the third dispersion; S6, water is added to the third dispersion to bring it to a final volume, and homogenization is performed to obtain the perampanel oral suspension. This method can significantly improve the dissolution rate, long-term stability, and control level of drug-related substances at day 0, and improve the uniformity of content.

The invention belongs to the technical field of pharmaceutical analysis, and provides a detection method of a brexpiprazole oral suspension, which adopts reverse high performance liquid chromatography for detection, can realize effective separation of brexpiprazole and impurities thereof, can also realize effective separation of brexpiprazole and impurities thereof and preservatives, is simple and convenient to operate, has good specificity and high sensitivity, and can be applied to detection of oral suspension of brexpiprazole. The control requirement of the limit of 0.5% is met, and the method can be used for quality control of the brexpiprazole oral suspension.

The disclosed embodiment relates to a palatable icosapent ethyl formulation with statin. More particularly, the formulation comprises of icosapent ethyl, antioxidant, statin, alkalizer, wetting agent, suspending agent, diluent, flavouring agent, and sweetening agent. Furthermore, the statin is rosuvastatin calcium; the antioxidant is tocopherol; the alkalizer is magnesium oxide; the wetting agent is docusate sodium; the suspending agent is colloidal silicon dioxide; the diluent is miglyol 812; the flavouring agent is peppermint oil; and the sweetening agent is sucralose. The said formulation is an oral suspension for reduction of triglyceride (TG) levels and stabilization of atherosclerotic plaque.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a paliperidone long-acting oral suspension based on ion exchange resin and a preparation method of the paliperidone long-acting oral suspension. The cation exchange resin and the paliperidone are adopted to form a medicine-resin compound, pH responsive release is achieved through ionic bonds, and the effects of low dissociation in gastric juice and slow release in intestinal juice are achieved; meanwhile, a ready-to-use oral suspension is developed for patients with dysphagia, a flavoring agent is added, the taste is improved, compared with controlled release tablets, the compliance of the patients can be improved, the medication convenience can be improved, and the paliperidone long-acting oral suspension preparation has a good application prospect.

The invention discloses a sevelamer carbonate dry suspension and a preparation method thereof.The sevelamer carbonate dry suspension is prepared from, by mass, 94.81%-95.07% of a sevelamer carbonate raw material, 0.11%-1.30% of a suspending aid and other auxiliary materials, and the suspending aid is selected from one or more of sodium carboxymethyl cellulose, a microcrystalline cellulose-sodium carboxymethyl cellulose compound, xanthan gum and hydroxypropyl methylcellulose. Compared with the prior art, the sevelamer carbonate dry suspension has the advantages that the sevelamer carbonate raw material in the sevelamer carbonate dry suspension is high in proportion, and the suspending aid in the sevelamer carbonate dry suspension is low in proportion, so that grit feeling caused by oral administration of the suspension is effectively reduced, the stability and taste of the suspension are improved, the deposition speed of the medicine suspension is reduced, and a patient can uniformly take in the medicine when taking the sevelamer carbonate dry suspension; the method is particularly important for patients suffering from dysphagia or oral sensitivity.

This document discloses rivaroxaban tablets for oral suspension formulation for oral administration. Also disclosed is a method for preparing rivaroxaban tablets for oral suspension and a method of treating diseases.

The present invention relates to a tadalafil oral suspension comprising 0.01-5% w / v of tadalafil, a cyclodextrin, coprocessed microcrystalline cellulose and sodium carboxymethyl cellulose, xanthan gum and water as vehicle. The suspensions are chemically and physically stable and show a dissolution profile equivalent to that of commercial tadalafil film-coated tablets. The tadalafil suspensions are suitable for treating male erectile dysfunction and benign prostatic hyperplasia. The invention also relates to a fixed-dose combination dosage forms comprising said tadalafil suspension and either tamsulosin, in particular, in the form of modified-release pellets, or dutasteride. Said combined forms are useful for treating lower urinary tract symptoms associated with benign prostatic hyperplasia. The invention also relates to a process for the preparation of said tadalafil composition.

A powder including Valaciclovir or pharmaceutical acceptable salt or derivative thereof and an ion exchange resin. The Valaciclovir is in complex with the ion exchange resin forming Drug-Resin complex (DRC) particles, and each DRC particle comprises hydrogen bonds between the ion exchange resin and a cationic center of Valaciclovir. The ratio of Valaciclovir to the ion exchange resin in the DRC particle is 1:0.5. The powder further includes a suspending agent and a pH agent, and the suspending agent forms a film around each DRC particle and the film decreases interparticle attraction. The powder is configured to be reconstituted with an aqueous diluent as suspension for oral administration.

The invention belongs to the technical field of pharmaceutical preparations, and relates to a brexpiprazole oral suspension and a preparation method thereof. Comprising the following steps: adding brexpiprazole and a suspending aid into propylene glycol, and uniformly mixing to obtain a solution 1; adding a preservative and a sweetening agent into water, and uniformly mixing to prepare a solution 2; and uniformly mixing the solution 1 and the solution 2 to obtain a finished product. According to the prepared brexpiprazole oral suspension, not only can the content uniformity of brexpiprazole be higher, but also palatability and compliance of patients (especially old people, children or patients with swallowing dysfunction) can be provided, and therefore it is guaranteed that drugs play the expected treatment effect.